DYN
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
Article Summary
HOLD- Dyne Therapeutics Inc. (Nasdaq: DYN) announced pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at a public offering price of $20.50 per share, with gross proceeds to Dyne from the offering expected to be $375,150,000.
- The clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases granted the underwriters a 30-day option to purchase up to 2,745,000 additional shares.
- The offering is expected to close on or about July 23, 2026 subject to customary closing conditions.
- Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering, with LifeSci Capital and Raymond James acting as lead managers.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 15.4% | 25% | 50.0 ptsMeets Minimum (15.4%) - Passes screener |
| Target Price Upside ? | 65.0% | 20% | 100.0 ptsMassive Upside (65.0%) - Target: $39.33 vs Current: $23.83 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -4.7% | 15% | 20.0 ptsBarely a Dip (-4.7%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About DYN
- Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
- The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
- Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.